<DOC>
	<DOC>NCT02842749</DOC>
	<brief_summary>To evaluate safety and efficacy of everolimus (AfinitorÂ®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.</brief_summary>
	<brief_title>Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma, Islet Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must have histological confirmed G1 or G2 pancreatic neuroendocrine tumors(pNETs) (WHO 2010) Patients must have radiological documentation of progression of disease per RECIST 1.1 within 12 months prior to enrollment. Measurable disease per RECIST 1.1 criteria using triphasic computed tomography (CT) scan or multiphase MRI for radiologic assessment. everolimus treatment which is recommended by the treating physician Hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients. Patient who is unwilling to receive Afinitor treatment due to any reason. Pregnant or nursing (lactating) women, Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus). Use of an investigational drug within the 30 days prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>